KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT (2016 - 2025)

Historic EBT for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $9.0 million.

  • Jazz Pharmaceuticals' EBT fell 9550.07% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$392.5 million, marking a year-over-year decrease of 19845.36%. This contributed to the annual value of $470.4 million for FY2024, which is 5787.35% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' EBT stood at $9.0 million, which was down 9550.07% from -$735.6 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year EBT high stood at $200.8 million for Q3 2024, and its period low was -$735.6 million during Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' median EBT value was $15.0 million (recorded in 2022), while the average stood at -$24.7 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' EBT crashed by 65840.51% in 2022 and then soared by 77116.21% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' EBT stood at -$44.8 million in 2021, then tumbled by 658.41% to -$340.0 million in 2022, then skyrocketed by 118.1% to $61.5 million in 2023, then soared by 116.52% to $133.2 million in 2024, then plummeted by 93.22% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, -$735.6 million for Q2 2025, and $133.2 million during Q4 2024.